Felix Biotechnology has announced the initiation of a research project with Biocogent, the leading provider of high technology products and services to the personal care and cosmetic industries.

The research project is focused on developing proof of concept novel, chemical-free and safe solutions that can specifically target problematic bacteria in the skin microbiome.

While Felix is a biotechnology company focused on developing advanced therapeutics, its powerful technology platform can develop custom solutions for a variety of industries where microbial challenges could be more effectively managed.

"At Biocogent we are focused on providing our customers with access to a continuous resource of current scientific discoveries and cutting-edge research and development. The technology at Felix Biotechnology is novel and innovative, and we are excited to explore how these solutions can add value to our consumer products," said Paul Lawrence, Director of Bioscience Research and Product Development, Biocogent.

"Leveraging the potential of our technology across a range of applications allows us to have the biggest impact possible and we are very excited to be working with a leader in the personal care and cosmetic space like Biocogent on this project," said Natalie Ma, Head of Business Development, Felix Biotechnology.